1997 Annual Report
Product Review Financials Setting
  | Financial Highlights | Financial Review |
| Management’s Report | Audit Committee’s Report |
| Independent Auditors’ Report | Financial Statements
| Notes to Financial Statements |
| Directors, Committees, and Officers |
| Corporate and Shareholder Information |
| Consolidated Income |
| Consolidated Balance Sheet |
| Consolidated Shareholder’s Equity |
| Consolidated Cash Flows |
| Segment Information | Geographic Data |
| Quarterly Data | Financial Summary |
 

  Geographic Data
  Pfizer Inc and Subsidiary Companies

(millions of dollars)   United  
States(6)
Europe Asia Canada/
Latin
America
Africa/
Middle
East
Corporate/
Other
Adjustments/
Eliminations
Consolidated 
Total revenues 1997   $6,867   $2,853   $1,675   $849   260   $      —       $      —     $12,504(1)
  1996   5,941   2,773   1,598   750   244   $      —       $      —     $11,306    
  1995   5,113   2,444   1,538   696   230   $      —       $      —     $10,021    
Intercompany sales 1997   196   881   75   64   11      —       (1,227)      —     
  1996   197   813   84   35   9      —       (1,138)      —     
  1995   175   692   75   29   10      —       (981)      —     
Total 1997   7,063   3,734   1,750   913   271      —       (1,227)   12,504(1)
  1996   6,138   3,586   1,682   785   253      —       (1,138)   11,306    
  1995   5,288   3,136   1,613   725   240      —       (981)   10,021    
Geographic profit/(loss) 1997   2,251   1,012   233   42   7   (372)(2)   (85)   3,088(3)
  1996   2,018   1,013   250   29   (5)   (423)(2)   (78)   2,804(3)
  1995   1,628   778   261   49   12   (382)(2)   (47)   2,299(3)
Identifiable assets(7) 1997   4,665   4,317   1,202   570   151   5,599      (1,168)   15,336   
  1996   4,424   4,072   1,278   606   174   5,265      (1,152)   14,667   
  1995   3,199   3,647   1,243   612   193   4,796(5)   (961)   12,729   

(1)Includes alliance revenue of $316 million.

(2)Includes interest income/(expense) and corporate expenses. Also includes other income/(expense) of the financial subsidiaries (see note 3, “Financial Subsidiaries”).

(3)Consolidated total equals income from continuing operations before provision for taxes on income and minority interests.

(4)Certain production facilities are shared by various segments. Property, plant and equipment, as well as capital additions and depreciation, are allocated based on physical production. Corporate assets are primarily cash, short-term investments and long-term marketable securities.

(5)Includes amounts for the food science business which was sold in 1996.

(6)Includes operations in Puerto Rico.

(7)Products are transferred between geographic areas for additional processing and ultimate sale, on a basis intended to recognize economic and competitive circumstances in the market of end use. These figures reflect the physical location of assets even though these assets provide goods and services to other areas.

  letter back top next
  Logo Imagemap
  intended for investors
  Advisory Information for Investors
  Copyright © 1997, 1998 Pfizer Inc All rights reserved.